Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 symbols : ALNY save search
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection
Published: 2022-09-22 (Crawled : 13:20) - biospace.com/
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -1.55%
H: 2.68%
C: 1.2%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: -1.26%
vir-2218 treatment hepatitis vir-3434 virus trial infection phase 2
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Published: 2022-08-29 (Crawled : 13:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.08%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: -0.64%
H: 1.24%
C: 0.07%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.56%
H: 1.41%
C: -0.34%
treatment nephropathy positive study phase 2
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
Published: 2022-06-09 (Crawled : 12:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: 0.0%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 1.59%
H: 0.68%
C: -2.46%
treatment nephropathy topline positive phase 2
New Results from Phase 1 Study of Cemdisiran + Pozelimab Presented at ASH Annual Meeting 2021
Published: 2021-12-14 (Crawled : 03:00) - alnylam.com
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 6.02%
H: 2.03%
C: -0.29%
phase 1 results phase 2 phase 3
Alnylam Initiates KARDIA-2 Phase 2 Study of Investigational Zilebesiran (ALN-AGT) in Patients with Inadequately Controlled Hypertension
Published: 2021-11-08 (Crawled : 13:00) - biospace.com/
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 1.43%
H: 0.0%
C: 0.0%
phase 2 hypertension
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-07-21 (Crawled : 13:00) - biospace.com/
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: 0.9%
H: 0.72%
C: 0.58%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.58%
H: 0.42%
C: 0.38%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -2.13%
disease liver disease treatment phase 1 results liver trial phase 2 phase 3
Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection
Published: 2021-07-15 (Crawled : 14:00) - biospace.com/
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: 0.08%
H: 2.71%
C: 2.31%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.16%
H: 1.35%
C: 1.11%
phase 2 hepatitis biotech technology iot trial injection infections chronic hepatitis b
Alnylam Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN-AGT) in Patients with Mild-to-Moderate Hypertension
Published: 2021-06-30 (Crawled : 12:00) - biospace.com/
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: -0.28%
H: 5.14%
C: 2.48%
phase 2 hypertension
Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-06-22 (Crawled : 12:15) - biospace.com/
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: -0.39%
H: 0.27%
C: -0.21%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: -0.02%
H: 0.44%
C: -0.53%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.08%
H: 1.01%
C: 0.9%
disease liver disease treatment phase 2 liver trial
Complete Results from Phase 1/2 Study of Lumasiran (OXLUMO®) Published in Clinical Journal of the American Society of Nephrology
Published: 2021-05-15 (Crawled : 04:20) - alnylam.com
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
| Email alert
Add to watchlist
phase 1 results phase 3 phase 2
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
Published: 2021-04-21 (Crawled : 12:00) - vbivaccines.com
VIR | $7.96 -3.52% -3.64% 880K
|
Health Technology
|
| O: -1.09%
H: 0.38%
C: 0.04%
VBIV | $0.6001 -1.46% -1.48% 180K
|
Health Technology
|
| O: 0.0%
H: 7.66%
C: 7.66%
ALNY | News | $145.045 -0.19% -0.19% 400K
|
Health Technology
|
| O: 0.67%
H: 1.12%
C: 0.43%
treatment phase 2 hepatitis vbi-2601 biotech vaccine technology iot brii-835 trial
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.